Harvard Bioscience Statistics
Total Valuation
HBIO has a market cap or net worth of $43.17 million. The enterprise value is $84.52 million.
Important Dates
The next estimated earnings date is Thursday, March 6, 2025, before market open.
| Earnings Date | Mar 6, 2025 |
| Ex-Dividend Date | n/a |
Share Statistics
HBIO has 43.61 million shares outstanding. The number of shares has increased by 2.68% in one year.
| Current Share Class | 43.61M |
| Shares Outstanding | 43.61M |
| Shares Change (YoY) | +2.68% |
| Shares Change (QoQ) | +0.29% |
| Owned by Insiders (%) | 7.55% |
| Owned by Institutions (%) | 65.91% |
| Float | 35.02M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | 8.25 |
| PS Ratio | 0.44 |
| Forward PS | 0.44 |
| PB Ratio | 0.66 |
| P/TBV Ratio | n/a |
| P/FCF Ratio | 51.09 |
| P/OCF Ratio | 10.75 |
| PEG Ratio | n/a |
Financial Ratio HistoryEnterprise Valuation
The stock's EV/EBITDA ratio is 29.33, with an EV/FCF ratio of 100.02.
| EV / Earnings | n/a |
| EV / Sales | 0.86 |
| EV / EBITDA | 29.33 |
| EV / EBIT | n/a |
| EV / FCF | 100.02 |
Financial Position
The company has a current ratio of 2.06, with a Debt / Equity ratio of 0.70.
| Current Ratio | 2.06 |
| Quick Ratio | 0.76 |
| Debt / Equity | 0.70 |
| Debt / EBITDA | 9.15 |
| Debt / FCF | 54.34 |
| Interest Coverage | -1.36 |
Financial Efficiency
Return on equity (ROE) is -20.40% and return on invested capital (ROIC) is -2.32%.
| Return on Equity (ROE) | -20.40% |
| Return on Assets (ROA) | -1.98% |
| Return on Invested Capital (ROIC) | -2.32% |
| Return on Capital Employed (ROCE) | -3.96% |
| Revenue Per Employee | $234,933 |
| Profits Per Employee | -$34,233 |
| Employee Count | 416 |
| Asset Turnover | 0.72 |
| Inventory Turnover | 1.56 |
Taxes
In the past 12 months, HBIO has paid $883,000 in taxes.
| Income Tax | 883,000 |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -77.14% in the last 52 weeks. The beta is 1.25, so HBIO's price volatility has been higher than the market average.
| Beta (5Y) | 1.25 |
| 52-Week Price Change | -77.14% |
| 50-Day Moving Average | 1.85 |
| 200-Day Moving Average | 2.57 |
| Relative Strength Index (RSI) | 16.00 |
| Average Volume (20 Days) | 284,482 |
Short Selling Information
The latest short interest is 758,606, so 1.74% of the outstanding shares have been sold short.
| Short Interest | 758,606 |
| Short Previous Month | 785,126 |
| Short % of Shares Out | 1.74% |
| Short % of Float | 2.17% |
| Short Ratio (days to cover) | 3.03 |
Income Statement
In the last 12 months, HBIO had revenue of $97.73 million and -$14.24 million in losses. Loss per share was -$0.33.
| Revenue | 97.73M |
| Gross Profit | 57.40M |
| Operating Income | -4.29M |
| Pretax Income | -9.43M |
| Net Income | -14.24M |
| EBITDA | 2.88M |
| EBIT | -4.29M |
| Loss Per Share | -$0.33 |
Full Income StatementBalance Sheet
The company has $4.57 million in cash and $45.91 million in debt, giving a net cash position of -$41.35 million or -$0.95 per share.
| Cash & Cash Equivalents | 4.57M |
| Total Debt | 45.91M |
| Net Cash | -41.35M |
| Net Cash Per Share | -$0.95 |
| Equity (Book Value) | 65.32M |
| Book Value Per Share | 1.50 |
| Working Capital | 24.04M |
Full Balance SheetCash Flow
In the last 12 months, operating cash flow was $4.02 million and capital expenditures -$3.17 million, giving a free cash flow of $845,000.
| Operating Cash Flow | 4.02M |
| Capital Expenditures | -3.17M |
| Free Cash Flow | 845,000 |
| FCF Per Share | $0.02 |
Full Cash Flow StatementMargins
Gross margin is 58.73%, with operating and profit margins of -4.39% and -14.57%.
| Gross Margin | 58.73% |
| Operating Margin | -4.39% |
| Pretax Margin | -13.67% |
| Profit Margin | -14.57% |
| EBITDA Margin | 2.95% |
| EBIT Margin | -4.39% |
| FCF Margin | 0.86% |